Table 2.
Comparison of Baseline Characteristics According to the Best Response
| Characteristic | CR (n=5) | PR (n=25) | SD (n=40) | PD (n=41) | p-value |
|---|---|---|---|---|---|
| Age, yr | 64.0±17.4 | 60.7±10.8 | 62.0±11.2 | 57.6±10.8 | 0.297 |
| Male sex | 3 (60.0) | 20 (80.0) | 32 (80.0) | 32 (78.0) | 0.777 |
| Etiology | 0.162 | ||||
| Non-viral | 0 | 4 (16.0) | 13 (32.5) | 7 (17.1) | |
| Viral | 5 (100) | 21 (84.0) | 27 (67.5) | 34 (82.9) | |
| ALBI grade | 0.090 | ||||
| 1 | 5 (100) | 15 (60.0) | 23 (57.5) | 18 (43.9) | |
| 2 | 0 | 10 (40.0) | 17 (42.5) | 23 (56.1) | |
| AFP, ng/mL | 40.8 (40.7–160) | 6.8 (3.0–196) | 22.1 (7.4–543) | 343.0 (21.9–32,750) | 0.004 |
| PIVKA-II, mAU/mL | 575 (443–710) | 631 (54.0–7,481) | 401 (71.0–5,126) | 580 (58.0–4,776) | 0.991 |
| CRP, mg/dL | 0.2 (0.1–0.4) | 0.9 (0.2–2.5) | 0.8 (0.2–2.1) | 0.7 (0.2–3.9) | 0.414 |
| NLR | 0.896 | ||||
| ≤4.0 | 4 (80.0) | 18 (72.0) | 32 (80.0) | 32 (78.0) | |
| >4.0 | 1 (20.0) | 7 (28.0) | 8 (20.0) | 9 (22.0) | |
| CTP class | 0.313 | ||||
| A | 5 (100.0) | 22 (88.0) | 39 (97.5) | 36 (87.8) | |
| B | 0 | 3 (12.0) | 1 (2.5) | 5 (12.2) | |
| CRAFITY score* | 0.337 | ||||
| 0 | 3 (75.0) | 6 (35.3) | 7 (29.2) | 7 (23.3) | |
| 1 | 1 (25.0) | 9 (52.9) | 14 (58.3) | 15 (50.0) | |
| 2 | 0 | 2 (11.8) | 3 (12.5) | 8 (26.7) | |
| BCLC | 0.324 | ||||
| B | 1 (20.0) | 4 (16.0) | 7 (17.5) | 8 (19.5) | |
| C | 4 (80.0) | 21 (84.0) | 33 (82.5) | 33 (80.5) | |
| Macrovascular invasion | 0 | 11 (44.0) | 15 (37.5) | 16 (39.0) | 0.324 |
| High-risk features | 0 | 9 (36.0) | 15 (37.5) | 13 (31.7) | 0.401 |
| Prior local treatment | 4 (80.0) | 16 (64.0) | 21 (52.5) | 26 (63.4) | 0.544 |
| Combined RT | 1 (20.0) | 11 (44.0) | 10 (25.0) | 2 (4.9) | 0.002 |
| Lung metastasis | 0 | 3 (12.0) | 12 (30.0) | 14 (34.1) | 0.110 |
| LN metastasis | 1 (20.0) | 10 (40.0) | 10 (25.0) | 9 (22.0) | 0.411 |
| Bone metastasis | 2 (40.0) | 5 (20.0) | 6 (15.0) | 6 (14.6) | 0.513 |
| Peritoneal seeding | 3 (60.0) | 4 (16.0) | 2 (5.0) | 0 | <0.001 |
Data are presented as mean±standard deviation, number (%), or median (interquartile range).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ALBI, albumin-bilirubin; AFP, a-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; CTP, Child-Turcotte-Pugh; CRAFITY, C-reactive protein and α-fetoprotein in immunotherapy; BCLC, Barcelona Liver Cancer; RT, radiotherapy; LN, lymph node.
*Missing information on CRAFITY score for 36 patients.